Global Artificial Pancreas Device System Market to reach USD 1,116.86 million at a CAGR of 16.33% by 2032, Evaluates DelveInsight

According to DelveInsight's analysis, The global rise in diabetes prevalence is a major factor driving the artificial pancreas device market, as the expanding patient base fuels the need for advanced diabetes management solutions. Growing awareness initiatives and the implementation of screening programs have also enabled earlier diagnosis and improved disease control, boosting the demand for technologies like artificial pancreas systems. Additionally, continuous product innovation and development by leading market players have led to more efficient and user-friendly devices, improving accessibility for patients. Together, these factors are expected to propel the growth of the artificial pancreas device market throughout the forecast period from 2025 to 2032.

DelveInsight's "Artificial Pancreas Device System Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Pancreas Device System companies actively working in the market.

To know more about why North America is leading the market growth in the Artificial Pancreas Device System market, get a snapshot of the report Artificial Pancreas Device System Market Trends
https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Artificial Pancreas Device System Overview
An Artificial Pancreas Device System (APDS) is a medical technology designed to automatically monitor and regulate blood glucose levels in people with diabetes, particularly Type 1 diabetes. It mimics the function of a healthy pancreas by combining a continuous glucose monitor (CGM), an insulin pump, and a control algorithm that calculates and delivers the right insulin dose in real time. The system helps reduce the burden of frequent blood sugar checks and manual insulin administration, improving glycemic control and reducing the risk of hypoglycemia or hyperglycemia.

DelveInsight Analysis: The global artificial pancreas device market size was valued at USD 334.76 million in 2024, is expected to grow at a CAGR of 16.33% from 2025 to 2032, reaching approximately USD 1,116.86 million by the end of 2032.

Artificial Pancreas Device System Market Insights
Geographically, North America is projected to account for the largest share of the artificial pancreas device market in 2024. This leading position is attributed to the rising prevalence of diabetes, strong government healthcare initiatives, and the presence of major market players actively engaged in strategic product development. Additionally, growing public awareness about advanced diabetes management technologies across the region is further expected to drive market growth during the forecast period.

To read more about the latest highlights related to Artificial Pancreas Device System, get a snapshot of the key highlights entailed in the Artificial Pancreas Device System Market Insights
https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Artificial Pancreas Device System Market Report
• In September 2024, Tandem Diabetes Care, Inc., announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology was cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU).
• In June 2024, MCRA, a leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm, announced its role in assisting CamDiab's artificial pancreas software, CamAPS FX, in achieving U.S. Food and Drug Administration (FDA) clearance.
• Thus, owing to such developments in the market, rapid growth will be observed in the Artificial Pancreas Device System market during the forecast period

Key Players in the Artificial Pancreas Device System Market
Some of the key market players operating in the Artificial Pancreas Device System market include- Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and others.

Which MedTech key players in the Artificial Pancreas Device System market are set to emerge as the trendsetter explore @ Key Artificial Pancreas Device System Companies
https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Artificial Pancreas Device System Market Landscape
Moreover, the active participation of key industry players in strategic product development is significantly contributing to the growth of the artificial pancreas device market. For example, in March 2023, Tandem Diabetes Care, Inc., a leading company in insulin delivery and diabetes technology, published results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial in the New England Journal of Medicine. The findings revealed that children aged 2-5 years using the t:slimX2 insulin pump with Control-IQ hybrid closed-loop technology experienced an average increase of three hours per day in time-in-range, compared to those using traditional insulin pumps or multiple daily injections. All participants used the Dexcom G6 Continuous Glucose Monitoring (CGM) System.
Overall, such advancements and clinical successes are expected to further drive the artificial pancreas device market during the forecast period.

Scope of the Artificial Pancreas Device System Market Report
• Coverage: Global
• Study Period: 2022-2032
• Artificial Pancreas Device System Market Segmentation By Device Type: Threshold Suspended Device System and Non-Threshold Suspended Device System
• Artificial Pancreas Device System Market Segmentation By End-User: Hospitals & Clinics, Homecare Settings, Ambulatory Surgical Centers, and others
• Artificial Pancreas Device System Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Artificial Pancreas Device System Companies: Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Artificial Pancreas Device System market will grow by 2032? Click to get a snapshot of the Artificial Pancreas Device System Market Analysis
https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.